Navigate crucial prostate cancer treatment decisions – with the right answers at the right time.
Prolaris is a powerful tool that combines personalized information of tumor behavior with traditional clinical-pathological features to create the most prognostic information available. The Prolaris test offers unparalleled utility and unbiased insights to help you confidently recommend the best course of treatment for your patients.
Prolaris delivers a personalized risk assessment of a patient’s prostate cancer by combining clinically proven information with traditional diagnostic tools like PSA and Gleason.
Pathology offers a snapshot of how your patient’s cancer looks today, but it doesn’t give you the full picture. Prolaris combines traditional diagnostic tools like PSA, Gleason and tumor staging with an independent genomics score to tell — and show – what the cancer is doing, how it’s behaving, and potential outcomes from that behavior.
With Prolaris, you’ll save precious time and move your prostate cancer patients toward the right type of treatment from the beginning. Because the Prolaris test is done at the time of diagnosis and requires no additional biopsy, results can be available at your patient’s first cancer consult. Any untreated patient diagnosed with localized prostate cancer is a candidate for Prolaris testing.
Improving the patient experience through genomics
When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. Prolaris is the only test studied in untreated patients and can identify the MOST patients for active surveillance across all biomarkers.2 For patients and providers looking to make confident prostate cancer treatment decisions, Prolaris:
Molecular tests like Prolaris are supported by NCCN guidelines as a 2A recommendation, which is considered standard of care. Prolaris is the only biomarker test on the market with both a validated Active Surveillance Threshold and Multi-Treatment Modality Threshold, giving both patients and providers confidence with their treatment decisions.
In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients.4,5
Prolaris extends active surveillance candidate population by 62% compared to clinical and pathologic features alone.2
Prolaris is two times more prognostic than PSA/Gleason alone3
Prolaris has an independent CCP score that determines cancer aggressiveness and is combined with more traditional clinical pathological features like PSA and Gleason to create the most prognostic test on the market.
When it comes to treating prostate cancer, precision matters. So does quality of life. You want to ensure that your patients aren’t undertreated or overtreated. Prolaris can identify which men are safe for active surveillance and those who are not. With two clinically validated thresholds, Prolaris can also identify which patients should consider actively treating their cancer with one form of treatment, like surgery or radiation, and which patients will benefit from multiple forms of treatment.
Men with prostate cancer that is not considered to be aggressive may be safely monitored using Active Surveillance. Active Surveillance is the recommended management option for most men with lower risk cancers.
Men with more aggressive tumors should undergo treatment. The type and intensity (magnitude) of the treatment is usually tailored to the potential risk of the disease. The most common forms of treatment include surgical removal of the prostate or radiation therapy.
Men with very aggressive cancer may be offered multi-modal therapy. Multi-modality therapy employs two or more therapies planned at the treatment onset. National cancer guidelines offer suggestions as to which may be a more appropriate treatment option based on the patient’s risk and potential outcomes of the treatment.
Dr. Brian Richardson, urologist, discusses his experience using the Prolaris test to best treat his prostate cancer patients.
Learn more about how Prolaris can benefit a clinic and its patients.
Prolaris testing is simple and utilizes existing tissue from the diagnostic biopsy. No additional biopsies or blood draws are required. Myriad offers process experts to help customize ordering for your practice.
Myriad UroSuite gives healthcare providers the ability to directly order a complete suite of tests – including biomarker, germline and somatic – for clear, comprehensive insights to guide prostate cancer treatment.
Every Prolaris test provides actionable results to inform more confident prostate cancer treatment decisions.
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
Myriad believes in providing the most accurate and highest quality tests for patients. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answer possible.